1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €26.91 (+60.66%). The median is €27.56 (+64.54%).
| Buy |
Â
9 |
| Hold |
Â
5 |
| Sell |
Â
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -19.88M | 7.54% |
| EBITDA | -21.7M | 23.50% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €654.52M |
Number of shares | 37.14M |
52-week high/low | €23.61 - €7.51 |
| Dividends | No |
Beta | 1.23 |
P/E ratio | -2.70 |
PEG ratio | -0.01 |
P/B ratio | 3.83 |
P/S ratio | 63.95 |
Company profile
| Name | Crescent Biopharma Inc |
| CEO | Joshua T. Brumm |
| Employees | 44 |
